HGS Submits BLA For Interferon Zalbin For Hepatitis C
This article was originally published in The Pink Sheet Daily
Executive Summary
If approved, the interferon could offer a dosing advantage over pegylated interferons, although safety data could mean a bumpy regulatory road ahead.